Dagenet Caitlyn B, Lee Katrina H, Sayed Christopher, Hsiao Jennifer L, Shi Vivian Y
The University of Arizona College of Medicine, Tucson, AZ, USA.
Department of Dermatology, University of Southern California, Los Angeles, CA, USA.
Am J Clin Dermatol. 2025 Apr 3. doi: 10.1007/s40257-025-00940-0.
Management of hidradenitis suppurativa (HS) can be challenging and often requires a multimodal approach with use of on- and off-label medications. There has been a rapid expansion of available HS treatments in the years since the 2019 North American HS (NAHS) clinical management guidelines. Herein we present an up-to-date practical management algorithm based on the diagnosis and management strategies set forth by the 2019 NAHS guidelines using newly available literature. Evaluation and diagnosis of HS disease involves assessment of severity, extent of disease, and impact on patient quality of life. Initial diagnosis of HS should be shortly followed by comorbidity screening. The multimodal approach to HS treatment typically involves use of treatment stacking of topical therapies, systemic and topical antibiotics, retinoids, hormonal and metabolic therapies, biologics and small molecule inhibitors, systemic immunosuppressants, surgical treatment, pain management, lifestyle modifications, adjunctive treatment, wound care, and flare therapy. Thus, the proposed algorithm aims to guide clinicians in their implementation of treatment stacking in HS.
化脓性汗腺炎(HS)的管理具有挑战性,通常需要采用多模式方法,使用已批准和未批准的药物。自2019年北美HS(NAHS)临床管理指南发布以来,可用的HS治疗方法迅速增加。在此,我们根据2019年NAHS指南提出的诊断和管理策略,结合最新文献,给出一份最新的实用管理算法。HS疾病的评估和诊断涉及对严重程度、疾病范围以及对患者生活质量影响的评估。HS的初步诊断后应紧接着进行合并症筛查。HS治疗的多模式方法通常包括局部治疗、全身和局部抗生素、维甲酸、激素和代谢疗法、生物制剂和小分子抑制剂、全身免疫抑制剂、手术治疗、疼痛管理、生活方式改变、辅助治疗、伤口护理和发作期治疗的联合应用。因此,所提出的算法旨在指导临床医生在HS中实施联合治疗。